Determination of the Optimal Procalcitonin Threshold for Infection in Patients With Impaired Renal Function at a Community Hospital

被引:3
作者
Bowman, Caitlin [1 ]
Covington, Elizabeth W. [1 ]
机构
[1] Samford Univ, Birmingham, AL USA
关键词
procalcitonin; renal insufficiency; sepsis; pneumonia; acute kidney injury; chronic renal insufficiency; chronic renal failure; SERUM PROCALCITONIN; DISEASES-SOCIETY; GUIDELINES; MANAGEMENT; PNEUMONIA;
D O I
10.1177/8755122520924803
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Procalcitonin (PCT) is a biomarker that can help identify bacterial infections but can be difficult to interpret in the presence of renal dysfunction, which can elevate PCT even in the absence of infection. Objective: To determine the optimal PCT threshold to identify infection in patients with renal dysfunction and pneumonia or sepsis. Methods: A retrospective analysis was performed for inpatients with creatinine clearance of <= 60 mL/min and PCT level from 2018 to 2019. A pharmacist blinded to study outcomes classified patients as infected or noninfected based on predetermined criteria. Receiver operating characteristic curve analysis was performed to establish the optimal PCT threshold overall, as well as in subgroups of patients with chronic kidney disease (CKD), acute kidney injury (AKI), and end-stage renal disease (ESRD). Institutional review board approval was obtained. Results: A total of 198 patients were included in the study (99 infected, 99 noninfected). The optimal threshold in the AKI, CKD, and ESRD subgroups was determined to be 1.5 ng/mL, 0.1 ng/mL, and 1.75 ng/mL, respectively. Conclusion: The results of this study show that PCT thresholds were specific to type of renal dysfunction. These results differ from the traditionally accepted PCT threshold of 0.5 ng/mL for sepsis and 0.25 mg/mL for pneumonia. Future studies should confirm the appropriate PCT threshold in ESRD and CKD patient populations.
引用
收藏
页码:157 / 163
页数:7
相关论文
共 19 条
[1]   Procalcitonin (PCT) Predicts Worse Outcome in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF) [J].
Banach, J. ;
Wolowiec, L. ;
Rogowicz, D. ;
Gackowska, L. ;
Kubiszewska, I ;
Gilewski, W. ;
Michalkiewicz, J. ;
Sinkiewicz, W. .
DISEASE MARKERS, 2018, 2018
[2]   Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial [J].
Bouadma, Lila ;
Luyt, Charles-Edouard ;
Tubach, Florence ;
Cracco, Christophe ;
Alvarez, Antonio ;
Schwebel, Carole ;
Schortgen, Frederique ;
Lasocki, Sigismond ;
Veber, Benoit ;
Dehoux, Monique ;
Bernard, Maguy ;
Pasquet, Blandine ;
Regnier, Bernard ;
Brun-Buisson, Christian ;
Chastre, Jean ;
Wolff, Michel .
LANCET, 2010, 375 (9713) :463-474
[3]   Procalcitonin Monitoring as a Guide for Antimicrobial Therapy: A Review of Current Literature [J].
Covington, Elizabeth W. ;
Roberts, Megan Z. ;
Dong, Jenny .
PHARMACOTHERAPY, 2018, 38 (05) :569-581
[4]   Procalcitonin and C-reactive protein plasma concentrations in nonseptic uremic patients undergoing hemodialysis [J].
Dahaba, AA ;
Rehak, PH ;
List, WF .
INTENSIVE CARE MEDICINE, 2003, 29 (04) :579-583
[5]   Procalcitonin and Liver Disease: A Literature Review [J].
Dong, Ruolin ;
Wan, Bo ;
Lin, Su ;
Wang, Mingfang ;
Huang, Jiaofeng ;
Wu, Yinlian ;
Wu, Yilong ;
Zhang, Nanwen ;
Zhu, Yueyong .
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2019, 7 (01) :51-55
[6]   Foreword [J].
Eckardt, Kai-Uwe ;
Kasiske, Bertram L. .
KIDNEY INTERNATIONAL SUPPLEMENTS, 2012, 2 (01) :7-7
[7]   Sensitivity and Specificity of Procalcitonin in Predicting Bacterial Infections in Patients With Renal [J].
El-Sayed, Dena ;
Grotts, Jonathan ;
Golgert, William A. ;
Sugar, Alan M. .
OPEN FORUM INFECTIOUS DISEASES, 2014, 1 (02)
[8]   Use of Procalcitonin in Patients With Various Degrees of Chronic Kidney Disease Including Renal Replacement Therapy [J].
Grace, Eddie ;
Turner, R. Mackenzie .
CLINICAL INFECTIOUS DISEASES, 2014, 59 (12) :1761-1767
[9]   Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society [J].
Kalil, Andre C. ;
Metersky, Mark L. ;
Klompas, Michael ;
Muscedere, John ;
Sweeney, Daniel A. ;
Palmer, Lucy B. ;
Napolitano, Lena M. ;
O'Grady, Naomi P. ;
Bartlett, John G. ;
Carratala, Jordi ;
El Solh, Ali A. ;
Ewig, Santiago ;
Fey, Paul D. ;
File, Thomas M., Jr. ;
Restrepo, Marcos I. ;
Roberts, Jason A. ;
Waterer, Grant W. ;
Cruse, Peggy ;
Knight, Shandra L. ;
Brozek, Jan L. .
CLINICAL INFECTIOUS DISEASES, 2016, 63 (05) :E61-E111
[10]  
KDIGO Board Members: Kidney disease: improving global outcomes (KDIGO). Acute Kidney Injury Work Group, 2012, KIDNEY INT SUPPL, V2, P3